Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Capelle Aan Den Ijssel – page 56

1 543 clinical trials in Capelle Aan Den Ijssel, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Capelle Aan Den Ijssel at a glance
1 543
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 543 trials in Capelle Aan Den Ijssel

Open in trial search

Choroid melanoma

Not yet recruiting

Long‑Term Follow‑Up Study of Belzupacap Sarotalocan in Patients with Early Choroidal Melanoma

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Aura Biosciences Inc.

Optic ischaemic neuropathy

Not yet recruiting

Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Epcoritamab plus rituximab versus rituximab alone in elderly, frail or unfit patients with newly diagnosed diffuse large B‑cell lymphoma

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:65+ years
  • Substances:Epcoritamab
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Neoplasm

Not yet recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Evaluating the efficacy and safety of CRD-4730 in patients with heart failure with reduced ejection fraction

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:CRD-4730
  • Sponsor:Cardurion Pharmaceuticals Inc.

Gastric cancer+1

Not yet recruiting

Capecitabine drug combination in perioperative treatment for patients with gastric and esophageal cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Pleural mesothelioma

Not yet recruiting

Reducing Toxicity of Dual PD‑1 and CTLA‑4 Checkpoint Therapy in Pleural Mesothelioma Patients with Ustekinumab (anti‑p40)

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ustekinumab
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Brain injury

Not yet recruiting

Intranasal remestemcel therapy for newborns with hypoxic‑ischemic brain injury: a phase II placebo‑controlled trial

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years
  • Substances:Remestemcel
  • Sponsor:Universitair Medisch Centrum Utrecht

Infertility+2

Not yet recruiting

Micronised progesterone luteal-phase support improves live birth rates in women with unexplained infertility

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Sponsor:Universitair Medisch Centrum Utrecht

Bronchiectasis

Not yet recruiting

A Study of SAR445399 in Adults Aged 18‑80 with Non‑cystic Fibrosis Bronchiectasis

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:SAR445399
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Osteogenesis imperfecta

Not yet recruiting

Phase 2 Study of AGA2115 in Adults with Osteogenesis Imperfecta (COL1A1/COL1A2 Variants) Evaluating Bone Density

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:AGA2115
  • Sponsor:Angitia Inc. Ltd.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Capelle Aan Den Ijssel

What the registry says about research in the country

01 Oncology - Colorectal Studies

Multiple innovative trials focusing on colorectal cancer treatment strategies, including research on liver metastases management and chemotherapy optimization for older patients.

  • Hepatic arterial infusion therapy
  • Dose-adjusted chemotherapy protocols
  • Post-surgical treatment approaches

Advanced research exploring both surgical and medical interventions for improved patient outcomes.

02 Hematology & Breast Cancer

Groundbreaking studies in multiple myeloma treatment protocols and innovative approaches for hormone receptor-positive breast cancer management.

  • Treatment-free interval assessment
  • CDK 4/6 inhibition strategies
  • Endocrine therapy optimization

Focus on developing personalized treatment strategies for better long-term outcomes.

03 Inflammatory & Autoimmune Conditions

Comprehensive research on rheumatoid arthritis management, investigating novel treatment timing and personalized therapeutic approaches.

  • Chronotherapy effectiveness
  • Tailored management protocols
  • Cost-effectiveness analysis

Emphasis on patient-centered outcomes and treatment optimization.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.